{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:45:29Z","timestamp":1790192729754,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ijrobp.2016.03.047","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T09:55:46Z","timestamp":1460195746000},"page":"1443-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or\u00a0Without External Beam Radiation Therapy"],"prefix":"10.1016","volume":"95","author":[{"given":"Jonathan D.","family":"Tward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Jarosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C.","family":"Shrieve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2016.03.047_bib1","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Prostate Cancer version 1.2015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed April 20,\u00a02015."},{"key":"10.1016\/j.ijrobp.2016.03.047_bib2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2014.08.061","article-title":"Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both","volume":"67","author":"Jarosek","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ijrobp.2015.07.2290","article-title":"High-dose-rate monotherapy for localized prostate cancer: 10-Year results","volume":"94","author":"Hauswald","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","article-title":"Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer","volume":"94","author":"Jawad","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijrobp.2015.12.375","article-title":"High-dose-rate monotherapy for localized prostate cancer\u2014What more will it take to make this a standard therapy?","volume":"94","author":"Nguyen","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ijrobp.2015.05.044","article-title":"High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: Clinical results for a median 8-year follow-up","volume":"94","author":"Yoshioka","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib7","series-title":"Common Terminology Criteria for Adverse Events v4.0 [publication No. 09-7473]","year":"2009"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib8","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0962280210386207","article-title":"Diagnosing and responding to violations in the positivity assumption","volume":"21","author":"Petersen","year":"2012","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib12","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"Suppl","key":"10.1016\/j.ijrobp.2016.03.047_bib14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/jco.2015.33.7_suppl.116","article-title":"Grade 3 or higher morbidity requiring urologic surgical management following curative-intent radiotherapy of localized prostate cancer: Patient characteristics","volume":"33","author":"Thorpe","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ijrobp.2016.03.047_bib15","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.brachy.2012.04.002","article-title":"Brachytherapy provides comparable outcomes and improved cost-effectiveness in the treatment of low\/intermediate prostate cancer","volume":"11","author":"Shah","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5114\/jcb.2013.34342","article-title":"Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer\u2014Between options","volume":"5","author":"Skowronek","year":"2013","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib18","series-title":"Comparative Evaluation of Radiation Treatments for Clinically Localized Prostate Cancer: An Update","author":"Ip","year":"2010"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e3181b9cd2f","article-title":"High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer","volume":"33","author":"Martinez","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib20","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.ijrobp.2010.09.006","article-title":"High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: A phase II trial","volume":"82","author":"Barkati","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Pt B","key":"10.1016\/j.ijrobp.2016.03.047_bib21","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.1111\/j.1464-410X.2012.11436.x","article-title":"Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma","volume":"111","author":"Buckstein","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.juro.2007.08.136","article-title":"Long-term urinary sequelae following 125iodine prostate brachytherapy","volume":"179","author":"Crook","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.juro.2007.03.126","article-title":"Incidence of urethral stricture after primary treatment for prostate cancer: Data From CaPSURE","volume":"178","author":"Elliott","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.brachy.2008.09.004","article-title":"Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy","volume":"8","author":"Ghadjar","year":"2009","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib25","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.urology.2009.04.101","article-title":"Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer","volume":"75","author":"Gomez-Iturriaga Pina","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.juro.2012.08.091","article-title":"Severe genitourinary toxicity following radiation therapy for prostate cancer\u2013How Long Does it Last?","volume":"189","author":"Kim","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib27","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.ejca.2009.07.009","article-title":"Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991","volume":"45","author":"Matzinger","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib28","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ijrobp.2010.10.009","article-title":"Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer","volume":"82","author":"Mohammed","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","article-title":"Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate","volume":"23","author":"Sathya","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1754-9485.2012.02358.x","article-title":"HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre","volume":"56","author":"Whalley","year":"2012","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/1754-9485.12275","article-title":"Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: A comparison of Australian series","volume":"59","author":"Wilcox","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"4 Pt 1","key":"10.1016\/j.ijrobp.2016.03.047_bib32","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.juro.2006.06.002","article-title":"Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer","volume":"176","author":"Zelefsky","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijrobp.2006.08.030","article-title":"Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer","volume":"67","author":"Zelefsky","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib34","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.eururo.2007.12.030","article-title":"Long-term outcome following three-dimensional conformal\/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer","volume":"53","author":"Zelefsky","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib35","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1538-4721(02)00101-0","article-title":"LDR vs. HDR brachytherapy for localized prostate cancer: The view from radiobiological models","volume":"1","author":"King","year":"2002","journal-title":"Brachytherapy"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.semradonc.2008.04.004","article-title":"Point: The linear-quadratic model is an appropriate methodology for determining iso-effective doses at large doses per fraction","volume":"18","author":"Brenner","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib37","first-page":"113","article-title":"The case for hypofractionation of localized prostate cancer","volume":"15","author":"Wong","year":"2013","journal-title":"Rev Urol"},{"key":"10.1016\/j.ijrobp.2016.03.047_bib38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ctrv.2013.01.008","article-title":"Systematic review of hypofractionated radiation therapy for prostate cancer","volume":"39","author":"Zaorsky","year":"2013","journal-title":"Cancer Treat Rev"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616300372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301616300372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T10:23:46Z","timestamp":1536834226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301616300372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0360301616300372"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.047","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or\u00a0Without External Beam Radiation Therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2016.03.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}